Comparison of Oral and IV 18 F-NaF PET/CT Administration in the Assessment of Bone Metastases in Patients With Breast or Prostate Cancers.

Purpose: The aim of this study was to compare oral and IV administrations of 18 F-NaF PET/CT for detection of suspicious bone metastatic lesions of breast and prostate cancers.

Patients And Methods: Thirty-six patients with breast (n = 23) or prostate (n = 13) cancers and high risk for bone metastases were prospectively evaluated. All patients underwent 2 PET/CT studies after IV and oral 18 F-NaF administration within a 2 to 23 days interval between them.

Preliminary Comparison of PET/CT Studies Performed After Intravenous and Oral Administration of 18F-Fluoride.

A 78-year-old man with prostate cancer was referred for 18F-NaF PET/CT for assessing bone metastases. An 18F-NaF PET/CT study was performed after the intravenous administration of the radiopharmaceutical. Five days later, a second study was done after oral administration of the radiopharmaceutical as part of a research protocol.

PET/CT study performed after an oral administration of 18F-fluoride.

A 52-year-old woman with right breast cancer was referred for 18F-fluoride whole-body PET/CT for the assessment of bone metastases. The peripheral i.v.

Incidental finding of anterior cranial fossa meningioma on 18F-fluoride PET/CT.

The association of breast carcinoma and meningioma has been described. We report a case of anterior cranial fossa meningioma in a woman with breast cancer detected by (18)F-fluoride PET/CT. The whole-body (18)F-fluoride PET images demonstrate an intense intracranial focal radiotracer accumulation in the skull base.